Clinical pharmacology of deoxycoformycin

P. P. Major, R. P. Agarwal, D. W. Kufe

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). Twenty-one courses of DCF were administered to 13 patients ranging in age from 15 to 78 yr. Eight patients had T-cell disorders, and 5 patients had non-T-cell malignancies. The i.v. bolus dose was escalated from 5 to 30 mg/sq m/day, and the duration of the courses ranged from 1 to 5 days. The DCF plasma half-life ranged from 4.9 to 6.2 hr and was independent of dose. The dose-limiting toxicities involved the central nervous system (CNS) and the kidneys. Other toxicities included bronchitis, decreases in hematocrit, arthralgias, and myalgias. Mortality was encountered in 3 patients. These toxic effects may have been secondary to the accumulation of the metabolites adenosine and deoxyadenosine. Deoxyadenosine and adenosine were both detectable in plasma (10-6 M) and in urine (10-3 M). Two partial remissions were observed: one in a patient with T-cell ALL and another in a patient with mycosis fungoides. Minimal responses characterized by either declines in peripheral blast counts or partial resolution of adenopathy were observed in 5 other patients. No responses were observed in 6 patients. These observations suggest that DCF is effective in the treatment of T-cell lymphoid malignancies.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalBlood
Volume58
Issue number1
StatePublished - Jan 1 1981
Externally publishedYes

Fingerprint

Pentostatin
Clinical Pharmacology
T-cells
Adenosine
Toxicity
Adenosine Deaminase Inhibitors
Plasmas
Poisons
Neurology
Metabolites
T-Lymphocytes
Cells
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Mycosis Fungoides
Bronchitis
Myalgia
Arthralgia
Hematocrit
Half-Life
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Major, P. P., Agarwal, R. P., & Kufe, D. W. (1981). Clinical pharmacology of deoxycoformycin. Blood, 58(1), 91-96.

Clinical pharmacology of deoxycoformycin. / Major, P. P.; Agarwal, R. P.; Kufe, D. W.

In: Blood, Vol. 58, No. 1, 01.01.1981, p. 91-96.

Research output: Contribution to journalArticle

Major, PP, Agarwal, RP & Kufe, DW 1981, 'Clinical pharmacology of deoxycoformycin', Blood, vol. 58, no. 1, pp. 91-96.
Major PP, Agarwal RP, Kufe DW. Clinical pharmacology of deoxycoformycin. Blood. 1981 Jan 1;58(1):91-96.
Major, P. P. ; Agarwal, R. P. ; Kufe, D. W. / Clinical pharmacology of deoxycoformycin. In: Blood. 1981 ; Vol. 58, No. 1. pp. 91-96.
@article{a2925d8bef5f47ecab6057d1e490eb2b,
title = "Clinical pharmacology of deoxycoformycin",
abstract = "Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). Twenty-one courses of DCF were administered to 13 patients ranging in age from 15 to 78 yr. Eight patients had T-cell disorders, and 5 patients had non-T-cell malignancies. The i.v. bolus dose was escalated from 5 to 30 mg/sq m/day, and the duration of the courses ranged from 1 to 5 days. The DCF plasma half-life ranged from 4.9 to 6.2 hr and was independent of dose. The dose-limiting toxicities involved the central nervous system (CNS) and the kidneys. Other toxicities included bronchitis, decreases in hematocrit, arthralgias, and myalgias. Mortality was encountered in 3 patients. These toxic effects may have been secondary to the accumulation of the metabolites adenosine and deoxyadenosine. Deoxyadenosine and adenosine were both detectable in plasma (10-6 M) and in urine (10-3 M). Two partial remissions were observed: one in a patient with T-cell ALL and another in a patient with mycosis fungoides. Minimal responses characterized by either declines in peripheral blast counts or partial resolution of adenopathy were observed in 5 other patients. No responses were observed in 6 patients. These observations suggest that DCF is effective in the treatment of T-cell lymphoid malignancies.",
author = "Major, {P. P.} and Agarwal, {R. P.} and Kufe, {D. W.}",
year = "1981",
month = "1",
day = "1",
language = "English",
volume = "58",
pages = "91--96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Clinical pharmacology of deoxycoformycin

AU - Major, P. P.

AU - Agarwal, R. P.

AU - Kufe, D. W.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). Twenty-one courses of DCF were administered to 13 patients ranging in age from 15 to 78 yr. Eight patients had T-cell disorders, and 5 patients had non-T-cell malignancies. The i.v. bolus dose was escalated from 5 to 30 mg/sq m/day, and the duration of the courses ranged from 1 to 5 days. The DCF plasma half-life ranged from 4.9 to 6.2 hr and was independent of dose. The dose-limiting toxicities involved the central nervous system (CNS) and the kidneys. Other toxicities included bronchitis, decreases in hematocrit, arthralgias, and myalgias. Mortality was encountered in 3 patients. These toxic effects may have been secondary to the accumulation of the metabolites adenosine and deoxyadenosine. Deoxyadenosine and adenosine were both detectable in plasma (10-6 M) and in urine (10-3 M). Two partial remissions were observed: one in a patient with T-cell ALL and another in a patient with mycosis fungoides. Minimal responses characterized by either declines in peripheral blast counts or partial resolution of adenopathy were observed in 5 other patients. No responses were observed in 6 patients. These observations suggest that DCF is effective in the treatment of T-cell lymphoid malignancies.

AB - Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). Twenty-one courses of DCF were administered to 13 patients ranging in age from 15 to 78 yr. Eight patients had T-cell disorders, and 5 patients had non-T-cell malignancies. The i.v. bolus dose was escalated from 5 to 30 mg/sq m/day, and the duration of the courses ranged from 1 to 5 days. The DCF plasma half-life ranged from 4.9 to 6.2 hr and was independent of dose. The dose-limiting toxicities involved the central nervous system (CNS) and the kidneys. Other toxicities included bronchitis, decreases in hematocrit, arthralgias, and myalgias. Mortality was encountered in 3 patients. These toxic effects may have been secondary to the accumulation of the metabolites adenosine and deoxyadenosine. Deoxyadenosine and adenosine were both detectable in plasma (10-6 M) and in urine (10-3 M). Two partial remissions were observed: one in a patient with T-cell ALL and another in a patient with mycosis fungoides. Minimal responses characterized by either declines in peripheral blast counts or partial resolution of adenopathy were observed in 5 other patients. No responses were observed in 6 patients. These observations suggest that DCF is effective in the treatment of T-cell lymphoid malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0019521591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019521591&partnerID=8YFLogxK

M3 - Article

C2 - 6263381

AN - SCOPUS:0019521591

VL - 58

SP - 91

EP - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -